
A study involving 97 IgA nephropathy (IgAN) patients evaluated the efficacy of Telitacicept in reducing proteinuria. The study, conducted from April 1, 2021, to April 1, 2023, revealed significant reductions in proteinuria at 2, 4, and 6 months compared to baseline (P < 0.01), with median values decreasing from 2.3 g/day to 0.9 g/day. Although eGFR levels remained stable throughout the study period, the treatment was well-tolerated with no severe adverse effects reported. These findings suggest that Telitacicept, whether used alone or with steroids, can effectively reduce proteinuria in IgAN patients. Long-term benefits and kidney protection require confirmation in larger Phase III trials.
Like
Save
Share